{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:20:58Z","timestamp":1768987258856,"version":"3.49.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000009523","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T15:54:31Z","timestamp":1514390071000},"page":"e9523","source":"Crossref","is-referenced-by-count":7,"title":["Dabrafenib plus trametinib for compassionate use in metastatic melanoma"],"prefix":"10.1097","volume":"96","author":[{"given":"Salvador","family":"Mart\u00edn Algarra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virtudes","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fern\u00e1ndez-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel-\u00c1ngel","family":"Berciano-Guerrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karmele","family":"Mujika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Manzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Pu\u00e9rtolas Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainara","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delvys","family":"Rodr\u00edguez-Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Espinosa Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Medina Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"M\u00e1rquez-Rodas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rubi\u00f3-Casadevall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Eugenia","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Miguel","family":"Jurado Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Lecumberri Biurrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Palacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez de la Borbolla Artacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier P\u00e9rez","family":"Altozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Eugenia","family":"Castell\u00f3n Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almudena","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anabel","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidio","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Antonio","family":"L\u00f3pez Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-68-20210226","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N Engl J Med"},{"key":"R2-68-20210226","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur J Cancer"},{"key":"R3-68-20210226","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-3-319-22539-5_2","article-title":"Melanoma epidemiology and prevention","volume":"167","author":"Berwick","year":"2016","journal-title":"Cancer Treat Res"},{"key":"R4-68-20210226","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2133.2009.09324.x","article-title":"Predicting outcome in melanoma: where are we now?","volume":"161","author":"Jennings","year":"2009","journal-title":"Br J Dermatol"},{"key":"R5-68-20210226","doi-asserted-by":"crossref","first-page":"647684","DOI":"10.1155\/2012\/647684","article-title":"Metastatic behaviour in melanoma: timing, pattern, survival, and influencing factors","volume":"2012","author":"Tas","year":"2012","journal-title":"J Oncol"},{"key":"R6-68-20210226","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/annonc\/mdu573","article-title":"A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival","volume":"26","author":"Ugurel","year":"2015","journal-title":"Ann Oncol"},{"key":"R7-68-20210226","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology (Williston Park"},{"key":"R8-68-20210226","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"R9-68-20210226","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat Genet"},{"key":"R10-68-20210226","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00008390-200510000-00011","article-title":"Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases","volume":"15","author":"Kirschner","year":"2005","journal-title":"Melanoma Res"},{"key":"R11-68-20210226","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-68-20210226","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-68-20210226","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"R14-68-20210226","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"R16-68-20210226","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-68-20210226","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jdcr.2015.09.020","article-title":"Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: case report and review of the literature","volume":"1","author":"Garrett","year":"2015","journal-title":"JAAD Case Rep"},{"key":"R18-68-20210226","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1078155214527859","article-title":"Facing the challenges of new melanoma-targeted therapies: treatment of severe fevers associated with dabrafenib\/trametinib combination therapy","volume":"21","author":"Lindsay","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"R19-68-20210226","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1186\/s12885-015-1391-x","article-title":"Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report","volume":"15","author":"Kim","year":"2015","journal-title":"BMC Cancer"},{"key":"R20-68-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2014.2512","article-title":"Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor","volume":"25","author":"Galliker","year":"2015","journal-title":"Eur J Dermatol"},{"key":"R21-68-20210226","first-page":"3697","article-title":"Safety and effectiveness analysis of V600 BRAF-mutated metastatic melanoma (MM) patients (pts) from the dabrafenib (D) plus trametinib (T) named patient programme (NPP)\u2014DESCRIBE study","volume":"32","author":"Atkinson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R22-68-20210226","doi-asserted-by":"crossref","first-page":"501","DOI":"10.5301\/tj.5000539","article-title":"Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience","volume":"102","author":"Cavalieri","year":"2016","journal-title":"Tumori"},{"key":"R23-68-20210226","first-page":"1211","article-title":"Safety and efficacy analysis of patients (pts) from the dabrafenib (D) named patient programme (NPP) in patients with V600 BRAF-mutated metastatic melanoma (MM)\u2014DESCRIBE study","volume":"27","author":"Martin-Algarra","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"R24-68-20210226","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1158\/1078-0432.CCR-13-2054","article-title":"Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma","volume":"20","author":"Menzies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R25-68-20210226","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1158\/0008-5472.CAN-07-6787","article-title":"Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma","volume":"68","author":"Montagut","year":"2008","journal-title":"Cancer Res"},{"key":"R26-68-20210226","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"R27-68-20210226","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1517\/14656566.2016.1168805","article-title":"Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations","volume":"17","author":"Spain","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"R28-68-20210226","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"R29-68-20210226","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"R30-68-20210226","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:50:44Z","timestamp":1620960644000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712290-00068"}},"subtitle":["A STROBE-compliant retrospective observational postauthorization study"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":29,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009523","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}